 |
11 Diseases |  |
8 Trials |
|
8 Trials |  |
280 News |  |
| «1234» |
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap, Suprefact (buserelin acetate) / Sanofi
Journal: Comparison of clinical efficacy of long- versus short-acting gonadotrophin-releasing hormone agonists for pituitary down regulation in In vitro fertilisation cycles. (Pubmed Central) - Aug 20, 2020
While group B had a significantly higher number of hospital visits (P = 0.0001) as well as a higher number of injections (P = 0.0001), the mean cost of GnRHa and gonadotrophin used was significantly higher in Group A (P = 0.043). Single-dose long-acting GnRHa is as effective as daily dose short-acting GnRHa for pituitary desensitisation prior to controlled ovarian stimulation in IVF cycles.
- | Suprefact (buserelin acetate) / Sanofi, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
New P3 trial: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Aug 13, 2020
P3, N=2478, Not yet recruiting, Sponsor: NRG Oncology
- | Suprefact (buserelin acetate) / Sanofi, Depo-Estradiol (estradiol cypionate) / Pfizer
Journal: Factors associated with pregnancy rate in fixed-time embryo transfer in cattle under humid-tropical conditions of México. (Pubmed Central) - Jul 28, 2020
However, the logistic regression determined that the only significant factor on pregnancy rate was the type of embryo. In conclusion, pregnancy rate in FTET females was higher for in vivo embryos than for in vitro embryos in cows evaluated under humid tropical conditions in Mexico.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise. (Pubmed Central) - Jul 4, 2020
The authors received no specific funding for this work and disclose no conflicts of interest. N/A.
- | Suprefact (buserelin acetate) / Sanofi
Retrospective data, Journal: Association of pregnancy per artificial insemination with gonadotropin-releasing hormone and human chorionic gonadotropin administered during the luteal phase after artificial insemination in dairy cows: A meta-analysis. (Pubmed Central) - Apr 30, 2020
In conclusion, the present meta-analysis showed that the use of GnRH and hCG after AI should be focused on cows expected to have low or moderate fertility. Day and dose of treatment have to be considered as well.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Factors affecting estrus and ovulation time in weaned sows with induced ovulation by GnRH administration in different seasons. (Pubmed Central) - Apr 14, 2020
Sows that were weaned with lactation length of at least 20 days, litter weight less than 67 kg, or BCS of at least 3, had better responses to buserelin injection. High backfat reserve after weaning is important for ovulation induction response by buserelin injection.
- | letrozole / Generic mfg.
Journal: Comparison of letrozole with gonadotropin-releasing hormone agonist in frozen embryo transfer after recurrent implantation failure: An RCT. (Pubmed Central) - Apr 9, 2020
The number of positive results of the beta human chorionic gonadotropin test and detection of fetal heartbeat were not significantly different between the groups (p 0.05). The administration of letrozole and GnRH may produce similar pregnancy outcomes in FET.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Expression of prostaglandin (PG) D synthase lipocalin and hematopoietic type and PG D receptor during restart of spermatogenesis following downregulation using a slow release GnRH agonist implant in the dog. (Pubmed Central) - Mar 2, 2020
The highest ratio for H-PGDS and DP was observed in the dogs treated with buserelin acetate (PRG). Our data show that the PGDS-DP system is expressed in juvenile and adult canine testes and that downregulation of the testicular endocrine and germinative function significantly affects H-PGDS, L-PGDS and DP mRNA expression indicating a role in the regulation of spermatogenesis.
- Suprefact (buserelin acetate) / Sanofi
The use of hMG in expected good responders does not result in higher live birth rates () - Jan 16, 2020 - Abstract #Fertility2020FERTILITY_305;
Our data shows that rFSH monotherapy resulted in shorter duration of treatment and higher oocyte yield with no additional significant risk of OHSS. Our findings are limited by the observational non-randomised study design.
- metformin / Generic mfg.
Clinical twin pregnancy reported after delayed ICSI 24 hours post oocyte retrieval () - Jan 16, 2020 - Abstract #Fertility2020FERTILITY_257;
Delayed ICSI reportedly achieves poorer outcomes. However, performing delayed ICSI could give specific patients opportunity for a successful outcome where they would otherwise have a cancelled cycle.
- Suprefact (buserelin acetate) / Sanofi
Elective freeze all (segmentation) results in higher clinical pregnancy rates in women with high AMH () - Dec 16, 2019 - Abstract #Fertility2020FERTILITY_118;
The low implantation rate in fresh treatment cycles may be related to higher progesterone levels in the follicular phase in GnRH-antagonist cycles (Bosch et al, 2010). Segmentation and subsequent frozen embryo transfer allows the use of Buserelin-only triggering, thus minimising the risk of OHSS, but patients must be counselled that there may be no embryos suitable for vitrification
- | Suprefact (buserelin acetate) / Sanofi
Journal: Hot-melt preparation of a non-biodegradable peptide implant: A proof of principle. (Pubmed Central) - Nov 2, 2019
Segmentation and subsequent frozen embryo transfer allows the use of Buserelin-only triggering, thus minimising the risk of OHSS, but patients must be counselled that there may be no embryos suitable for vitrification These results indicate the feasibility of preparing non-biodegradable peptide-loaded implants using the hot-melt production method and may act as a proof of principle concept for further innovation in peptide medicinal formulations.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Effects of implants containing the GnRH agonist deslorelin on testosterone release and semen characteristics in Shetland stallions. (Pubmed Central) - Oct 11, 2019
There was no difference among groups at any time during the study in percentage of motile and membrane-intact spermatozoa and sperm with DNA fragmentation. In conclusion, deslorelin implants modulate pituitary function in stallions but not to an extent that affects testicular function.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Effect of Oxytocin, Cloprostenol or Buserelin in Semen Doses on Sow Fertility. (Pubmed Central) - Oct 3, 2019
Litter size was larger (p ≤ 0.001) for all seminal additive groups during the first two periods and tended to increase in GN compared to CON (p ≤ 0.1) during the third period, resulting in a tendency (p < 0.1) for a period × treatment interaction. The addition of cloprostenol, oxytocin or buserelin to semen doses at first insemination increases litter size in multiparous sows.
- | Suprefact (buserelin acetate) / Sanofi
Preclinical, Journal: Promising activity of Anthemis austriaca Jacq. on the endometriosis rat model and isolation of its active constituents. (Pubmed Central) - Sep 15, 2019
As a conclusion, the MeOH extract obtained from A. austriaca flowers contributed to the regression of endometriosis. In addition, flavonoids and sterols of the plant were detected as the possible compounds responsible for the activity.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Effect of addition of buserelin acetate to the extender on motility and viability of bovine spermatozoa. (Pubmed Central) - Sep 11, 2019
The addition of buserelin acetate to BIOXcell extender did positively affect the total motility (was higher in the observed samples with the addition of 2 µg/mL and 4 µg/mL than in the control group), progressive motile (forward progressing sperm was significantly increased (p < 0.05) over the control group at the 0 h and 8 h of incubation following the supplementation of 2, 4 and 8 μg/mL buserelin acetate) and viability of spermatozoa (the number of live spermatozoa was significantly higher (p < 0.05) in 2 µg/mL and 4 µg/mL samples with buserelin acetate at 8th hour of incubation and in sample with 4 µg/mL at 24th hour of incubation compared to the control group). We recommend adding 4 µg/mL to the extender to improve the quality of bovine semen.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Effect of prostaglandin F2α and GnRH administration at the time of artificial insemination on reproductive performance of dairy cows. (Pubmed Central) - Jul 25, 2019
There was no significant difference between groups in terms of the offspring gender. In conclusion, the administration of d-cloprostenol or buserelin acetate at the time of AI had no effect on P/AI and pregnancy survival rate in dairy cattle under no heat stress condition, while the administration of d-cloprostenol increased the probability of twin pregnancies.
- | Suprefact (buserelin acetate) / Sanofi
Review, Journal: The Role of Tocotrienol in Preventing Male Osteoporosis-A Review of Current Evidence. (Pubmed Central) - Jul 12, 2019
However, information pertaining to its mechanism of actions is superficial and warrants further studies. As a conclusion, tocotrienol could serve as a functional food component to prevent male osteoporosis, but its application requires validation from a clinical trial in men.
- ||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Jul 5, 2019
P=N/A, N=461, Completed, Sponsor: Ferring Pharmaceuticals
As a conclusion, tocotrienol could serve as a functional food component to prevent male osteoporosis, but its application requires validation from a clinical trial in men. Active, not recruiting --> Completed
- | Suprefact (buserelin acetate) / Sanofi
Clinical, Journal: Endometrial Preparation for Women Undergoing Embryo Transfer Frozen-Thawed Embryo Transfer With and Without Pretreatment With Gonadotropin Releasing Hormone Agonists. (Pubmed Central) - Jun 27, 2019
Comparing outcome of FTET between the two groups scheduled for receiving GnRH agonist showed no significant difference in the rate of implantation (6.7% versus 10.0%), the rate of chemical pregnancy (21.7% versus 22.5%), clinical pregnancy rate (15.0% versus 17.5%), and also ongoing pregnancy (13.3% versus 12.5%). Endometrial preparation for FTET using GnRH agonists appears to be as effective as FTET without administrating these agonists.
- | Suprefact (buserelin acetate) / Sanofi
Journal: Daily administration of a GnRH analogue enhances sperm quality in bucks during the non-breeding season. (Pubmed Central) - Apr 17, 2019
The square root percentage of sperm with loose but heads with normal structures tended to be less in treated than control bucks (1.3 ± 0.3% compared with 0.4 ± 0.3% respectively, P = 0.06). It was concluded that daily administration of buserelin during the non-breeding season led to a rapid increase in testosterone concentration and improved sperm quality.
- | orteronel (TAK 700) / Takeda
Trial completion date, Trial primary completion date: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 14, 2019
P3, N=239, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
It was concluded that daily administration of buserelin during the non-breeding season led to a rapid increase in testosterone concentration and improved sperm quality. Trial completion date: Jun 2024 --> Jun 2029 | Trial primary completion date: Jun 2020 --> Jun 2025
- || Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=430, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial completion date: Jun 2024 --> Jun 2029 | Trial primary completion date: Jun 2020 --> Jun 2025 Trial completion date: Dec 2020 --> Jun 2019 | Trial primary completion date: Dec 2020 --> Jun 2019
- || Firmagon (degarelix) / Astellas, Ferring
Phase classification: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Mar 27, 2018
P, N=430, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial completion date: Dec 2020 --> Jun 2019 | Trial primary completion date: Dec 2020 --> Jun 2019 Phase classification: P=N/A --> P
- buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: NCMPC-BKM: Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 26, 2017
P1, N=6, Terminated, Sponsor: Institut Paoli-Calmettes
Phase classification: P=N/A --> P Trial primary completion date: Aug 2017 --> Nov 2017
- | orteronel (TAK 700) / Takeda
Enrollment change: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - May 19, 2017
P3, N=239, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Aug 2017 --> Nov 2017 N=900 --> 239
- || Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Apr 24, 2017
P=N/A, N=430, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
N=900 --> 239 Recruiting --> Active, not recruiting
- buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: NCMPC-BKM: Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer (clinicaltrials.gov) - Mar 3, 2017
P1, N=6, Terminated, Sponsor: Institut Paoli-Calmettes
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Aug 2017
- buparlisib (AN2025) / Adlai Nortye
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: NCMPC-BKM: Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 31, 2017
P1, N=6, Terminated, Sponsor: Institut Paoli-Calmettes
Trial primary completion date: Jan 2017 --> Aug 2017 N=18 --> 6 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2017; Defect of recruitment
- Suprefact (buserelin acetate) / Sanofi
Enrollment change, Trial termination, Trial primary completion date: Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles (clinicaltrials.gov) - Dec 23, 2016
P4, N=194, Terminated, Sponsor: Andros Day Surgery Clinic
N=18 --> 6 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2017; Defect of recruitment N=360 --> 194 | Recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Jul 2016; Optimal response: 63% nomogram, 42% controls, overcoming the stopping rule for interim analysis
- Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Sep 29, 2016
P3, N=1538, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
N=360 --> 194 | Recruiting --> Terminated | Trial primary completion date: Mar 2015 --> Jul 2016; Optimal response: 63% nomogram, 42% controls, overcoming the stopping rule for interim analysis Trial primary completion date: Dec 2020 --> May 2022
- Suprefact (buserelin acetate) / Sanofi
Enrollment open: Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation (clinicaltrials.gov) - Jun 16, 2016
P4, N=276, Recruiting, Sponsor: Mount Sinai Hospital, Canada
Trial primary completion date: Dec 2020 --> May 2022 Not yet recruiting --> Recruiting
- || Firmagon (degarelix) / Astellas, Ferring
Enrollment change, Trial primary completion date: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Apr 22, 2016
P=N/A, N=500, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting N=1500 --> 500 | Trial primary completion date: Mar 2020 --> Dec 2020
- | Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 9, 2016
P3, N=1538, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
N=1500 --> 500 | Trial primary completion date: Mar 2020 --> Dec 2020 Recruiting --> Active, not recruiting
- | Suprefact (buserelin acetate) / Sanofi
New P4 trial: Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation (clinicaltrials.gov) - Mar 9, 2016
P4, N=276, Not yet recruiting, Sponsor: Mount Sinai Hospital, Canada
- buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: NCMPC-BKM: Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 26, 2016
P1, N=18, Recruiting, Sponsor: Institut Paoli-Calmettes
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- || Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=1500, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Dec 2018 --> Mar 2020
- buparlisib (AN2025) / Adlai Nortye
New P1 trial, Combination therapy, Metastases: NCMPC-BKM: Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer (clinicaltrials.gov) - Jul 2, 2015
P1, N=18, Recruiting, Sponsor: Institut Paoli-Calmettes
- Suprefact (buserelin acetate) / Sanofi
Trial initiation date, Trial suspension, Trial primary completion date: Efficacy of Ovarian Stimulation Based on FSHR Genotype Status (clinicaltrials.gov) - May 5, 2015
P3, N=165, Suspended, Sponsor: Medical University of Vienna
Trial primary completion date: Dec 2018 --> Mar 2020 Initiation date: Jan 2009 --> May 2015 | Not yet recruiting --> Suspended | Trial primary completion date: Jan 2011 --> May 2015
- ||||| Suprefact (buserelin acetate) / Sanofi
Enrollment closed, Surgery: RTOG 0534: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer (clinicaltrials.gov) - Apr 1, 2015
P3, N=1792, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Initiation date: Jan 2009 --> May 2015 | Not yet recruiting --> Suspended | Trial primary completion date: Jan 2011 --> May 2015 Recruiting --> Active, not recruiting
- Suprefact (buserelin acetate) / Sanofi
Trial primary completion date: Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles (clinicaltrials.gov) - Jan 28, 2015
P4, N=360, Recruiting, Sponsor: Andros Day Surgery Clinic
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Mar 2015
- ||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: ProComD: Therapy Pathways in the Treatment of Hormone Na (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=1500, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Oct 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- ||||| orteronel (TAK 700) / Takeda
Enrollment closed: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Oct 10, 2014
P3, N=900, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Firmagon (degarelix) / Astellas, Ferring
Clinical: ProComD: Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (clinicaltrials.gov) - Sep 9, 2014
P=N/A, N=1500, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- | Suprefact (buserelin acetate) / Sanofi
Enrollment closed: Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy (clinicaltrials.gov) - Mar 13, 2014
P3, N=400, Active, not recruiting, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Enrollment change: Antagonist/Letrozole in Poor Responders (clinicaltrials.gov) - Dec 19, 2013
P1/2, N=120, Completed, Sponsor: Yazd Research & Clinical Center for Infertility
Recruiting --> Active, not recruiting N=180 --> 120
- letrozole / Generic mfg.
Trial completion: Antagonist/Letrozole in Poor Responders (clinicaltrials.gov) - Dec 19, 2013
P1/2, N=120, Completed, Sponsor: Yazd Research & Clinical Center for Infertility
N=180 --> 120 Recruiting --> Completed
- Suprefact (buserelin acetate) / Sanofi
Trial initiation date: Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles (clinicaltrials.gov) - Sep 24, 2013
P4, N=384, Completed, Sponsor: Regionshospitalet Viborg, Skive
Recruiting --> Completed Initiation date: Jan 2008 --> Jan 2009
- Suprefact (buserelin acetate) / Sanofi
Enrollment change: Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles (clinicaltrials.gov) - Sep 24, 2013
P4, N=384, Completed, Sponsor: Regionshospitalet Viborg, Skive
Initiation date: Jan 2008 --> Jan 2009 N=600 --> 384
- Suprefact (buserelin acetate) / Sanofi
Trial completion: Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles (clinicaltrials.gov) - Sep 24, 2013
P4, N=384, Completed, Sponsor: Regionshospitalet Viborg, Skive
N=600 --> 384 Recruiting --> Completed